Diet-Treated Gestational Diabetes Mellitus Is an Underestimated Risk Factor for Adverse Pregnancy Outcomes: A Swedish Population-Based Cohort Study
- PMID: 36014870
- PMCID: PMC9414969
- DOI: 10.3390/nu14163364
Diet-Treated Gestational Diabetes Mellitus Is an Underestimated Risk Factor for Adverse Pregnancy Outcomes: A Swedish Population-Based Cohort Study
Abstract
In Sweden, diet-treated gestational diabetes mellitus (GDM) pregnancies have been managed as low risk. The aim was to evaluate the risk of adverse perinatal outcomes among women with diet-treated GDM compared with the background population and with insulin-treated GDM. This is a population-based cohort study using national register data between 1998 and 2012, before new GDM management guidelines and diagnostic criteria in Sweden were introduced. Singleton pregnancies (n = 1,455,580) without pregestational diabetes were included. Among 14,242 (1.0%) women diagnosed with GDM, 8851 (62.1%) were treated with diet and 5391 (37.9%) with insulin. In logistic regression analysis, the risk was significantly increased in both diet- and insulin-treated groups (vs. background) for large-for-gestational-age newborns, preeclampsia, cesarean section, birth trauma and preterm delivery. The risk was higher in the insulin-treated group (vs. diet) for most outcomes, but perinatal mortality rates neither differed between treatment groups nor compared to the background population. Diet as a treatment for GDM did not normalize pregnancy outcomes. Pregnancies with diet-treated GDM should therefore not be considered as low risk. Whether changes in surveillance and treatment improve outcomes needs to be evaluated.
Keywords: diabetes in pregnancy; diet therapy; gestational diabetes; insulin; pregnancy outcomes.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- IDF Diabetes Atlas. 10th ed. The International Diabetes Federation; Brussels, Belgium: 2021. [(accessed on 9 May 2022)]. Available online: https://diabetesatlas.org/data/en/indicators/14/
-
- Metzger B.E., Lowe L.P., Dyer A.R., Trimble E.R., Chaovarindr U., Coustan D.R., Hadden D.R., McCance D.R., Hod M., McIntyre H.D., et al. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 2008;358:1991–2002. - PubMed
-
- Metzger B.E., Gabbe S.G., Persson B., Buchanan T.A., Catalano P.A., Damm P., Dyer A.R., de Leiva A., Hod M., Kitzmiler J.L., et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–682. doi: 10.2337/dc10-0719. - DOI - PMC - PubMed
-
- Fadl H.E., Gardefors S., Hjertberg R., Nord E., Persson B., Schwarcz E., Aman J., Ostlund I.K., Hanson U.S. Randomized controlled study in pregnancy on treatment of marked hyperglycemia that is short of overt diabetes. Acta Obstet. Et Gynecol. Scand. 2015;94:1181–1187. doi: 10.1111/aogs.12717. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
